Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is Segmented by Treatment Type (Glycerol Phenylbutyrate, Sodium Phenylbutyrate, Sodium Phenylacetate and Sodium Benzoate, and Other Treatment Types), Route of Administration (Oral and Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The Report Offers Market Sizes and Forecasts in Terms of Value (USD) for all the Above Segments.

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Ornithine Transcarbamylase Deficiency Treatment Market Size

OTC Deficiency Treatment Market size and growth rate (CAGR) chart from 2025 to 2030
Study Period 2019 - 2030
Market Size (2025) USD 0.86 Billion
Market Size (2030) USD 1.06 Billion
CAGR (2025 - 2030) 4.30 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Top five companies in the OTC Deficiency Treatment Market

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Ornithine Transcarbamylase (OTC) Deficiency Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Ornithine Transcarbamylase Deficiency Treatment Market Analysis

The Ornithine Transcarbamylase Deficiency Treatment Market size is estimated at USD 0.86 billion in 2025, and is expected to reach USD 1.06 billion by 2030, at a CAGR of 4.3% during the forecast period (2025-2030).

Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder showing a complete or partial lack of the ornithine transcarbamylase (OTC) enzyme. The rising approvals for novel pipeline products for ornithine transcarbamylase (OTC) deficiency treatment are expected to influence market growth. In March 2024, iECURE received the Medicines & Healthcare Products Regulatory Agency (MHRA) approval for its clinical trial authorization application (CTA) to expand the phase I/II OTC-HOPE clinical trial of its investigational gene editing-based therapy, ECUR-506, in the United Kingdom.

In addition, in August 2023, Bloomsbury Genetic Therapies Limited received orphan drug designation from the US Food and Drug Administration (FDA) for the company's investigational liver-targeted gene therapy, BGT-OTCD, for the treatment of ornithine transcarbamylase deficiency.

Furthermore, growing awareness for ornithine transcarbamylase deficiency disease and increasing campaigns organized by public and private entities are expected to fuel market growth. For instance, the NIH's National Center for Advancing Translational Sciences (NCATS) and the NIH Clinical Center sponsor the event, Rare Disease Day, on the last day of February, i.e., 28 or 29, as a part of the global Rare Disease Day observance every year. This day celebrates and includes raising awareness about rare diseases, the people they affect, etc. NIH conducted this event on February 29, 2024, and held it in person at the NIH Main Campus (Natcher Conference Center), Bethesda, United States.

In addition, favorable reimbursement scenarios in developed countries and patient assistance programs, particularly in developing regions, have also been fueling the growth of the OTC deficiency treatment market in recent years. For instance, in January 2024, Medunik USA, a member of Duchesnay Pharmaceutical Group (DPG), announced that Pheburane coverage is added to the Medicaid Preferred Drug List in 10 states with the recent addition of Indiana, Tennessee, Georgia, and Missouri, along with those already in effect in New Hampshire, New Mexico, North Dakota, Oklahoma, Texas, and Utah. Pheburane is also included on the California Contract Drugs List, and no prior authorization is required for the drug. Hence, it is easily accessible to patients with reimbursement. The drug is covered by commercial insurance plans, mainly offered by private players, and is covered by employers, which constitutes around 80% of the total commercially insured US population.

Medunik USA offers a patient program called the UNIK Support Program for Pheburanr, which provides specialized services, including a copay savings program, patient care liaison services, mail-order pharmacy, and other support services. Thus, the factors above are expected to boost the market growth.

However, the high cost of drugs, limited budget, and less awareness of disease and treatment in lower-income countries may restrain the market growth.

Ornithine Transcarbamylase Deficiency Treatment Industry Overview

The ornithine transcarbamylase (OTC) deficiency treatment market is consolidated due to key players capturing the bulk of market share globally and regionally. The competitive landscape includes an analysis of a few international and local companies with substantial market shares. Some key players include Amgen Inc. (Horizon Therapeutics PLC), Bausch Health Companies Inc., Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics Inc., Zevra Therapeutics (Acer Therapeutics), iECURE, Danone Group (Nutricia), Abbott, Reckitt Benckiser, Nestle, Moderna Inc., Duchesnay Pharmaceutical Group-DPG (Medunik USA), and Eurocept Pharmaceuticals Holding (Lucane Pharma).

Ornithine Transcarbamylase Deficiency Treatment Market Leaders

  1. Amgen Inc. (Horizon Therapeutics plc)

  2. Bausch Health Companies Inc.

  3. Ultragenyx Pharmaceutical Inc.

  4. Arcturus Therapeutics, Inc.

  5. Zevra Therapeutics (Acer Therapeutics)

  6. *Disclaimer: Major Players sorted in no particular order
Market concentration analysis of the OTC Deficiency Treatment Market
Need More Details on Market Players and Competiters?
Download PDF

Ornithine Transcarbamylase Deficiency Treatment Market News

  • November 2023: Zevra Therapeutics Inc. acquired Acer Therapeutics Inc., which marked an important milestone in executing Zevra's strategy to become a leader in products of treatments for rare diseases such as urea cycle disorders.
  • October 2023: Amgen acquired Horizon Therapeutics PLC with a valuation of around USD 27.8 billion. This acquisition strengthened Amgen's position in the rare disease portfolio market.
  • December 2022: Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA, announced the US Food and Drug Administration (FDA) approval for OLPRUVA (sodium phenylbutyrate) for oral suspension in the United States. This drug is indicated for the treatment of urea cycle disorders (UCDs), including OTC deficiency.

Ornithine Transcarbamylase Deficiency Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Product Approvals With Novel Pipeline Products for Ornithine Transcarbamylase (OTC) Deficiency Treatment
    • 4.2.2 Growing Awareness for Disease with Campaigns Organized by Public and Private Entities
    • 4.2.3 Favorable Reimbursement Scenario and Patient Assistance Programs
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Drugs and Limited Budget
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Treatment Type
    • 5.1.1 Glycerol Phenylbutyrate
    • 5.1.2 Sodium Phenylbutyrate
    • 5.1.3 Sodium Phenylacetate and Sodium Benzoate
    • 5.1.4 Other Treatment Types (Gene Therapy, Dietary Supplements, etc.)
  • 5.2 By Route of Administration
    • 5.2.1 Oral
    • 5.2.2 Intravenous
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
    • 5.3.4 Other Distribution Channels (Specialty Stores, Convenience Stores, etc.)
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Rest of the World

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc. (Horizon Therapeutics PLC)
    • 6.1.2 Bausch Health Companies Inc.
    • 6.1.3 Ultragenyx Pharmaceutical Inc.
    • 6.1.4 Arcturus Therapeutics Inc.
    • 6.1.5 Zevra Therapeutics (Acer Therapeutics)
    • 6.1.6 iECURE
    • 6.1.7 Danone Group (Nutricia)
    • 6.1.8 Abbott
    • 6.1.9 Reckitt Benckiser
    • 6.1.10 Nestle
    • 6.1.11 Moderna, Inc.
    • 6.1.12 Duchesnay Pharmaceutical Group-DPG(Medunik�USA)
    • 6.1.13 Eurocept Pharmaceuticals Holding (Lucane Pharma)
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Ornithine Transcarbamylase Deficiency Treatment Industry Segmentation

Ornithine transcarbamylase deficiency is a rare genetic condition that results in ammonia building up in the blood. This condition is more prominently seen in boys than girls and tends to be more severe when symptoms emerge shortly after birth. Ornithine transcarbamylase deficiency is caused by changes in the OTC gene, which instructs the body to make the OTC enzyme. In OTC deficiency, the OTC gene is either damaged or missing.

The ornithine transcarbamylase (OTC) deficiency treatment market is segmented into treatment type, route of administration, distribution channel, and geography. The market is segmented by treatment type into glycerol phenylbutyrate, sodium phenylbutyrate, sodium phenylacetate and sodium benzoate, and other treatment types. By route of administration, the market is segmented into oral and intravenous. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. The report also offers the market sizes and forecasts for 13 countries across the region. For each segment, the market size and forecast are provided in terms of value (USD).

By Treatment Type Glycerol Phenylbutyrate
Sodium Phenylbutyrate
Sodium Phenylacetate and Sodium Benzoate
Other Treatment Types (Gene Therapy, Dietary Supplements, etc.)
By Route of Administration Oral
Intravenous
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels (Specialty Stores, Convenience Stores, etc.)
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Need A Different Region or Segment?
Customize Now

Ornithine Transcarbamylase Deficiency Treatment Market Research FAQs

How big is the Ornithine Transcarbamylase Deficiency Treatment Market?

The Ornithine Transcarbamylase Deficiency Treatment Market size is expected to reach USD 0.86 billion in 2025 and grow at a CAGR of 4.30% to reach USD 1.06 billion by 2030.

What is the current Ornithine Transcarbamylase Deficiency Treatment Market size?

In 2025, the Ornithine Transcarbamylase Deficiency Treatment Market size is expected to reach USD 0.86 billion.

Who are the key players in Ornithine Transcarbamylase Deficiency Treatment Market?

Amgen Inc. (Horizon Therapeutics plc), Bausch Health Companies Inc., Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics, Inc. and Zevra Therapeutics (Acer Therapeutics) are the major companies operating in the Ornithine Transcarbamylase Deficiency Treatment Market.

Which is the fastest growing region in Ornithine Transcarbamylase Deficiency Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Ornithine Transcarbamylase Deficiency Treatment Market?

In 2025, the North America accounts for the largest market share in Ornithine Transcarbamylase Deficiency Treatment Market.

What years does this Ornithine Transcarbamylase Deficiency Treatment Market cover, and what was the market size in 2024?

In 2024, the Ornithine Transcarbamylase Deficiency Treatment Market size was estimated at USD 0.82 billion. The report covers the Ornithine Transcarbamylase Deficiency Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Ornithine Transcarbamylase Deficiency Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Ornithine Transcarbamylase Deficiency Treatment Industry Report

Statistics for the 2025 Ornithine Transcarbamylase (OTC) Deficiency Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Ornithine Transcarbamylase (OTC) Deficiency Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Ornithine-Transcarbamylase (OTC) Deficiency Treatment Market Report Snapshots